115 related articles for article (PubMed ID: 37129956)
21. Design, Synthesis, and Cytotoxic Evaluation of Certain 7-Chloro-4-(piperazin-1-yl)quinoline Derivatives as VEGFR-II Inhibitors.
Aboul-Enein MN; El-Azzouny AM; Ragab FA; Hamissa MF
Arch Pharm (Weinheim); 2017 Apr; 350(3-4):. PubMed ID: 28304102
[TBL] [Abstract][Full Text] [Related]
22. Discovery of N-(2-phenyl-1H-benzo[d]imidazol-5-yl)quinolin-4-amine derivatives as novel VEGFR-2 kinase inhibitors.
Shi L; Wu TT; Wang Z; Xue JY; Xu YG
Eur J Med Chem; 2014 Sep; 84():698-707. PubMed ID: 25064347
[TBL] [Abstract][Full Text] [Related]
23. Design, green synthesis, molecular docking and anticancer evaluations of diazepam bearing sulfonamide moieties as VEGFR-2 inhibitors.
Saleh NM; El-Gaby MSA; El-Adl K; Abd El-Sattar NEA
Bioorg Chem; 2020 Nov; 104():104350. PubMed ID: 33142416
[TBL] [Abstract][Full Text] [Related]
24. New bis([1,2,4]triazolo)[4,3-a:3',4'-c]quinoxaline derivatives as VEGFR-2 inhibitors and apoptosis inducers: Design, synthesis, in silico studies, and anticancer evaluation.
Alanazi MM; Mahdy HA; Alsaif NA; Obaidullah AJ; Alkahtani HM; Al-Mehizia AA; Alsubaie SM; Dahab MA; Eissa IH
Bioorg Chem; 2021 Jul; 112():104949. PubMed ID: 34023640
[TBL] [Abstract][Full Text] [Related]
25. Quinazoline based 1,3,5-triazine derivatives as cancer inhibitors by impeding the phosphorylated RET tyrosine kinase pathway: Design, synthesis, docking, and QSAR study.
Pathak P; Naumovich V; Grishina M; Shukla PK; Verma A; Potemkin V
Arch Pharm (Weinheim); 2019 Sep; 352(9):e1900053. PubMed ID: 31380598
[TBL] [Abstract][Full Text] [Related]
26. Synthesis, characterization, biological evaluation and molecular docking of a new quinazolinone-based derivative as a potent dual inhibitor for VEGFR-2 and EGFR tyrosine kinases.
Riadi Y; Alamri MA; Geesi MH; Anouar EH; Ouerghi O; Alabbas AB; Alossaimi MA; Altharawi A; Dehbi O; Alqahtani SM
J Biomol Struct Dyn; 2022 Sep; 40(15):6810-6816. PubMed ID: 33682611
[TBL] [Abstract][Full Text] [Related]
27. New Niflumic Acid Derivatives as EGFR Inhibitors: Design, Synthesis,
Yaseen YS; Mahmood AAR; Abbas AH; Shihab WA; Tahtamouni LH
Med Chem; 2023; 19(5):445-459. PubMed ID: 36537605
[TBL] [Abstract][Full Text] [Related]
28. Design, synthesis and biological evaluation of novel 4-anilinoquinazoline derivatives as hypoxia-selective EGFR and VEGFR-2 dual inhibitors.
Wei H; Duan Y; Gou W; Cui J; Ning H; Li D; Qin Y; Liu Q; Li Y
Eur J Med Chem; 2019 Nov; 181():111552. PubMed ID: 31387063
[TBL] [Abstract][Full Text] [Related]
29. Anti-tumor activity of erlotinib in the BxPC-3 pancreatic cancer cell line.
Lu YY; Jing DD; Xu M; Wu K; Wang XP
World J Gastroenterol; 2008 Sep; 14(35):5403-11. PubMed ID: 18803351
[TBL] [Abstract][Full Text] [Related]
30. Design, synthesis, biological evaluation and molecular modeling study of new thieno[2,3-d]pyrimidines with anti-proliferative activity on pancreatic cancer cell lines.
Salem MSH; Abdel Aziz YM; Elgawish MS; Said MM; Abouzid KAM
Bioorg Chem; 2020 Jan; 94():103472. PubMed ID: 31813475
[TBL] [Abstract][Full Text] [Related]
31. Design, microwave assisted synthesis, and molecular modeling study of some new 1,3,4-thiadiazole derivatives as potent anticancer agents and potential VEGFR-2 inhibitors.
Atta-Allah SR; AboulMagd AM; Farag PS
Bioorg Chem; 2021 Jul; 112():104923. PubMed ID: 33932767
[TBL] [Abstract][Full Text] [Related]
32. Molecular Docking, G-QSAR Studies, Synthesis and Anticancer Screening of Some New 2-Phenazinamines as Bcr-Abl Tyrosine Kinase Inhibitors.
Kale MA; Sonwane GM
Curr Drug Discov Technol; 2020; 17(2):213-224. PubMed ID: 30210004
[TBL] [Abstract][Full Text] [Related]
33. Angiokinase inhibition of VEGFR-2, PDGFR and FGFR and cell growth inhibition in lung cancer: Design, synthesis, biological evaluation and molecular docking of novel azaheterocyclic coumarin derivatives.
Ahmed EY; Elserwy WS; El-Mansy MF; Serry AM; Salem AM; Abdou AM; Abdelrahman BA; Elsayed KH; Abd Elaziz MR
Bioorg Med Chem Lett; 2021 Sep; 48():128258. PubMed ID: 34246754
[TBL] [Abstract][Full Text] [Related]
34. Discovery of thieno[2,3-d]pyrimidine-based derivatives as potent VEGFR-2 kinase inhibitors and anti-cancer agents.
El-Metwally SA; Abou-El-Regal MM; Eissa IH; Mehany ABM; Mahdy HA; Elkady H; Elwan A; Elkaeed EB
Bioorg Chem; 2021 Jul; 112():104947. PubMed ID: 33964580
[TBL] [Abstract][Full Text] [Related]
35. Design, Synthesis, In Silico and In Vitro Studies of New Immunomodulatory Anticancer Nicotinamide Derivatives Targeting VEGFR-2.
Yousef RG; Eldehna WM; Elwan A; Abdelaziz AS; Mehany ABM; Gobaara IMM; Alsfouk BA; Elkaeed EB; Metwaly AM; Eissa IH
Molecules; 2022 Jun; 27(13):. PubMed ID: 35807326
[TBL] [Abstract][Full Text] [Related]
36. Design, Synthesis and Antitumor Activities of Novel Quinazolinone Derivatives as Potential EGFR Inhibitors.
Wang J; Huang L; Chen X; Yuan Y; Sun J; Yang M
Chem Pharm Bull (Tokyo); 2022; 70(9):637-641. PubMed ID: 36047235
[TBL] [Abstract][Full Text] [Related]
37. Novel benzothiazole-based dual VEGFR-2/EGFR inhibitors targeting breast and liver cancers: Synthesis, cytotoxic activity, QSAR and molecular docking studies.
Abd El-Meguid EA; Naglah AM; Moustafa GO; Awad HM; El Kerdawy AM
Bioorg Med Chem Lett; 2022 Feb; 58():128529. PubMed ID: 35007724
[TBL] [Abstract][Full Text] [Related]
38. Phosphamide-containing diphenylpyrimidine analogues (PA-DPPYs) as potent focal adhesion kinase (FAK) inhibitors with enhanced activity against pancreatic cancer cell lines.
Liu H; Wu B; Ge Y; Huang J; Song S; Wang C; Yao J; Liu K; Li Y; Li Y; Ma X
Bioorg Med Chem; 2017 Dec; 25(24):6313-6321. PubMed ID: 29102081
[TBL] [Abstract][Full Text] [Related]
39. Design, synthesis and evaluation of novel 2-(1H-imidazol-2-yl) pyridine Sorafenib derivatives as potential BRAF inhibitors and anti-tumor agents.
Jiao Y; Xin BT; Zhang Y; Wu J; Lu X; Zheng Y; Tang W; Zhou X
Eur J Med Chem; 2015 Jan; 90():170-83. PubMed ID: 25461318
[TBL] [Abstract][Full Text] [Related]
40. Design, synthesis, and molecular docking of novel indole scaffold-based VEGFR-2 inhibitors as targeted anticancer agents.
Roaiah HM; Ghannam IAY; Ali IH; El Kerdawy AM; Ali MM; Abbas SE; El-Nakkady SS
Arch Pharm (Weinheim); 2018 Feb; 351(2):. PubMed ID: 29323750
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
